Ambachtenlaan 1

Heverlee 3001



Foundation date



#Biotechnology - Therapeutics


Therapeutic areas

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first-in-class Plug & Play vaccine platform with a patented DNA-based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

Latest news

  • Antonin (Tony) de Fougerolles appointed as new Chair of etherna

    Tuesday July 16th 2024

  • ONTOFORCE Achieves ISO 27001:2022 Certification: A Milestone in Information Security and Trust

    Tuesday July 16th 2024

  • Ghent University spin-off Trince wins Nature Spinoff Prize

    Monday July 15th 2024

Jobs by AstriVax